Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by RFG Advisory LLC

RFG Advisory LLC decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 47.5% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 11,820 shares of the biopharmaceutical company’s stock after selling 10,694 shares during the quarter. RFG Advisory LLC’s holdings in Gilead Sciences were worth $811,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Private Wealth Management Group LLC acquired a new stake in shares of Gilead Sciences during the fourth quarter valued at approximately $29,000. Palisade Asset Management LLC bought a new position in shares of Gilead Sciences in the first quarter valued at approximately $29,000. Sachetta LLC bought a new position in Gilead Sciences during the fourth quarter worth $30,000. Rakuten Securities Inc. bought a new position in Gilead Sciences during the fourth quarter worth $33,000. Finally, Gladius Capital Management LP acquired a new stake in shares of Gilead Sciences in the 4th quarter valued at $34,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $68.63, for a total transaction of $137,260.00. Following the completion of the transaction, the insider now owns 96,380 shares of the company’s stock, valued at $6,614,559.40. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.16% of the stock is currently owned by company insiders.

Gilead Sciences Stock Down 0.9 %

NASDAQ GILD traded down $0.67 during midday trading on Monday, hitting $72.99. 4,806,153 shares of the company traded hands, compared to its average volume of 7,380,031. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.08 and a quick ratio of 0.94. The company has a market cap of $90.93 billion, a PE ratio of 204.61, a price-to-earnings-growth ratio of 3.37 and a beta of 0.18. The company’s 50-day simple moving average is $69.81 and its 200-day simple moving average is $70.39. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $87.86.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 27th. Stockholders of record on Friday, September 13th will be given a $0.77 dividend. The ex-dividend date of this dividend is Friday, September 13th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.22%. Gilead Sciences’s payout ratio is 855.56%.

Wall Street Analysts Forecast Growth

GILD has been the topic of a number of research reports. Raymond James upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 target price on the stock in a research report on Monday, July 8th. HSBC upgraded Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 target price on the stock in a research report on Wednesday, April 24th. Morgan Stanley cut their price objective on Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating on the stock in a research note on Friday, April 26th. Royal Bank of Canada boosted their price objective on Gilead Sciences from $71.00 to $72.00 and gave the company a “sector perform” rating in a report on Friday. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $70.00 target price on shares of Gilead Sciences in a research report on Friday. Twelve analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $81.88.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.